RE: ESMO26 Aug 2024 15:34
Found 1 Presentation For Request "Ava6000"
Presentation TopicDevelopmental therapeutics
Filtered By
Developmental therapeutics
646P - A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Presentation Number
646P
Speakers
Christopher J. Twelves (Leeds, United Kingdom, Yorkshire)
Onsite Poster display date
Saturday, 14 September 2024